Could a cream stop scarring hair loss? small trial begins
NCT ID NCT07487948
First seen Mar 27, 2026 · Last updated Jun 22, 2026 · Updated 12 times
Summary
This pilot study tests a topical cream called delgocitinib in 30 adults with two types of scarring hair loss: lichen planopilaris and central centrifugal cicatricial alopecia. Participants apply the cream twice daily for 48 weeks. The study focuses on safety and changes in immune markers in the scalp, not yet on hair regrowth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CENTRAL CENTRIFUGAL CICATRICIAL ALOPECIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
delgocitinib cream
What this could lead to
If successful, this could point toward a new topical treatment for scarring hair loss conditions like lichen planopilaris and central centrifugal cicatricial alopecia.
What could go wrong
This is a small, early-phase pilot study with only 30 participants, so results may not apply to everyone. The main goal is safety and biomarker changes, not yet proving the drug stops hair loss.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.